- Published at
- by gurufocus.com
mixed
mixed
VIBATIV® RECEIVES MARKETING APPROVAL IN CHINA
PR NewswireNASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025
Vibativ® is a life-saving antibiotic for pneumonia and serious skin infectionsApproval in China pa
News for SciClone Pharmaceuticals (Holdings) Limited (6600.HK)
- Published at
- by prnewswire.com
neutralneutralMenarini et SciClone signent un accord de licence exclusif pour développer et commercialiser Vaborem® en Chine afin de traiter les infections résistantes aux antimicrobiens
Vaborem®, association brevetée de méropénème et de vaborbactam devrait permettre de faire face à la prévalence croissante des infections à Klebsiella...- Published at
- by prnewswire.com
negativenegativeMenarini und SciClone unterzeichnen exklusives Lizenzabkommen zur Entwicklung und Vermarktung von Vaborem® in China zur Behandlung antimikrobieller resistenter Infektionen
Vaborem®, eine patentierte Kombination aus Meropenem und Vaborbactam, soll die steigende Prävalenz von Carbapenem-resistenten Klebsiella pneumoniae (CRKP)...- Published at
- by prnewswire.com
neutralneutralSpoločnosti Menarini a SciClone podpísali exkluzívnu licenčnú zmluvu na vývoj a komercializáciu lieku Vaborem® v Číne, ktorý slúži na liečbu antimikrobiálne rezistentných infekcií
Očakáva sa, že Vaborem®, patentovaná kombinácia meropenému a vaborbaktámu, bude riešiť rastúci výskyt karbapeném-rezistentných infekcií Klebsiella pneumoniae...- Published at
- by prnewswire.com
positivepositiveMenarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections
Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae...- Published at
- by marketscreener.com
mixedmixedCUMBERLAND PHARMACEUTICALS REPORTS THIRD QUARTER 2021 FINANCIAL RESULTS & COMPANY UPDATE - Form 8-K
Cumberland Pharmaceuticals Inc. , a specialty pharmaceutical company, today is providing a company update and third quarter 2021 financial results. Net revenues from continuing operations during the... | November 9, 2021- Published at
- by globenewswire.com
neutralneutralY-mAbs Announces Priority Review of BLA for DANYELZA® (naxitamab-gqgk) in China
NEW YORK, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs” or the “Company”), NASDAQ: YMAB), a commercial-stage biopharmaceutical...- Published at
- by marketscreener.com
neutralneutralY mAbs Therapeutics : mAbs Announces NMPA Submission of BLA for DANELZA® (naxitamab-gqgk) in China (Form 8-K)
Y-mAbs Announces NMPA Submission of BLA for DANYELZA® in China New York, NY, July 6, 2021 -Y-mAbs Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused... | July 6, 2021- Published at
- by globenewswire.com
neutralneutralY-mAbs Announces NMPA Submission of BLA for DANYELZA® (naxitamab-gqgk) in China
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (“Y-mAbs”, NASDAQ: YMAB), a commercial-stage biopharmaceutical company focused on...